YHB Investment Advisors Inc. decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 4.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 76,594 shares of the biopharmaceutical company’s stock after selling 3,311 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Pfizer were worth $2,809,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in PFE. Front Street Capital Management Inc. grew its position in shares of Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares in the last quarter. Madison Wealth Management lifted its holdings in Pfizer by 0.6% during the 1st quarter. Madison Wealth Management now owns 42,810 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 262 shares in the last quarter. Capital Planning Advisors LLC lifted its holdings in Pfizer by 1.8% during the 2nd quarter. Capital Planning Advisors LLC now owns 16,091 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 281 shares in the last quarter. Gilbert & Cook Inc. lifted its holdings in Pfizer by 1.3% during the 1st quarter. Gilbert & Cook Inc. now owns 21,268 shares of the biopharmaceutical company’s stock worth $868,000 after purchasing an additional 283 shares in the last quarter. Finally, Live Oak Investment Partners grew its position in Pfizer by 2.2% during the second quarter. Live Oak Investment Partners now owns 13,415 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 286 shares in the last quarter. Institutional investors and hedge funds own 68.05% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 target price on shares of Pfizer in a research report on Monday, October 2nd. StockNews.com started coverage on Pfizer in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Jefferies Financial Group upgraded Pfizer from a “hold” rating to a “buy” rating and raised their price target for the company from $38.00 to $39.00 in a research report on Monday, October 16th. BMO Capital Markets cut their price target on shares of Pfizer from $44.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, October 16th. Finally, TheStreet cut shares of Pfizer from a “b-” rating to a “c+” rating in a research report on Monday, September 25th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $42.50.
Pfizer Trading Up 3.2 %
Shares of NYSE:PFE opened at $30.19 on Thursday. Pfizer Inc. has a 52-week low of $28.93 and a 52-week high of $54.93. The stock has a market cap of $170.47 billion, a price-to-earnings ratio of 16.50, a PEG ratio of 1.86 and a beta of 0.63. The company has a quick ratio of 2.05, a current ratio of 2.38 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $32.15 and a 200-day moving average price of $35.38.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.15. Pfizer had a return on equity of 16.72% and a net margin of 15.30%. The firm had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $13.77 billion. Equities analysts predict that Pfizer Inc. will post 1.56 EPS for the current year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Stockholders of record on Friday, November 10th will be issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 5.43%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 89.62%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- Where Do I Find 52-Week Highs and Lows?
- Is it time to buy the dip in Walmart shares?
- The Most Important Warren Buffett Stock for Investors: His Own
- Unlocking AI investment opportunities in healthcare
- 3 Healthcare Dividend Stocks to Buy
- New Disney investor propels stock to ranks of best S&P gainers
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.